Respiratory Medicine
Volume 104, Issue 11 , Pages 1608-1617 , November 2010

Omalizumab-induced decrease of FcɛRI expression in patients with severe allergic asthma

  • Pascal Chanez

      Affiliations

    • INSERM U 600, CNRS UMR 6212, Université de la Méditerranée, Marseille F-13009, France
    • Assistance Publique des Hôpitaux de Marseille, Département des Maladies Respiratoires, Marseille F-13009, France
    • ,
  • Cécile Contin-Bordes

      Affiliations

    • Université de Bordeaux, Bordeaux F-33000, France
    • CNRS UMR 5164, IFR 66, Bordeaux F-33000, France
    • Centre Hospitalier Universitaire de Bordeaux, Bordeaux F-33000, France
    • ,
  • Gilles Garcia

      Affiliations

    • Université Paris-Sud 11, Clamart F-92000, France
    • Hôpital Antoine Béclère, Assistance Publique des Hôpitaux de Paris, Service de Pneumologie et Réanimation Respiratoire, Clamart F-92000, France
    • ,
  • Christophe Verkindre

      Affiliations

    • Centre Hospitalier de Béthune, Béthune F-62400, France
    • ,
  • Alain Didier

      Affiliations

    • Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Toulouse F-31059, France
    • ,
  • Frédéric De Blay

      Affiliations

    • Pôle de Pathologie Thoracique, Hôpitaux Universitaires de Strasbourg, Strasbourg F-67000, France
    • Université de Strasbourg, Strasbourg F-67000, France
    • ,
  • Manuel Tunon de Lara

      Affiliations

    • Université de Bordeaux, Bordeaux F-33000, France
    • INSERM U855, Bordeaux F-33000, France
    • ,
  • Patrick Blanco

      Affiliations

    • Université de Bordeaux, Bordeaux F-33000, France
    • CNRS UMR 5164, IFR 66, Bordeaux F-33000, France
    • Centre Hospitalier Universitaire de Bordeaux, Bordeaux F-33000, France
    • ,
  • Jean-François Moreau

      Affiliations

    • Université de Bordeaux, Bordeaux F-33000, France
    • CNRS UMR 5164, IFR 66, Bordeaux F-33000, France
    • Centre Hospitalier Universitaire de Bordeaux, Bordeaux F-33000, France
    • ,
  • Philip Robinson

      Affiliations

    • INSERM CIC0005, Bordeaux F-33000, France
    • ,
  • Isabelle Bourdeix

      Affiliations

    • Novartis Pharma S.A.S., Rueil Malmaison F-92506, France
    • ,
  • Patrick Trunet

      Affiliations

    • Novartis Pharma S.A.S., Rueil Malmaison F-92506, France
    • ,
  • Vincent Le Gros

      Affiliations

    • Novartis Pharma S.A.S., Rueil Malmaison F-92506, France
    • ,
  • Marc Humbert

      Affiliations

    • Université Paris-Sud 11, Clamart F-92000, France
    • Hôpital Antoine Béclère, Assistance Publique des Hôpitaux de Paris, Service de Pneumologie et Réanimation Respiratoire, Clamart F-92000, France
    • ,
  • Mathieu Molimard

      Affiliations

    • Université de Bordeaux, Bordeaux F-33000, France
    • Centre Hospitalier Universitaire de Bordeaux, Bordeaux F-33000, France
    • INSERM, Unité 657, IFR 99, Université de Bordeaux, Département de Pharmacologie, CHU de Bordeaux, 33076 Bordeaux cedex, France
    • Corresponding Author InformationCorresponding author. INSERM, Unité 657, IFR 99, Université de Bordeaux, Département de Pharmacologie, CHU de Bordeaux, 33076 Bordeaux cedex, France. Tel.: +33 5 57 57 15 60; fax: +33 5 57 57 46 71.

Received 30 April 2010 ,Accepted 16 July 2010.

References 

  1. Passalacqua G, Ciprandi G. Allergy and the lung. Clin Exp Immunol. 2008;153(Suppl. 1):12–16
  2. Gaga M, Papageorgiou N, Yiourgioti G, Karydi P, Liapikou A, Bitsakou H, et al. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy. 2005;35:954–959
  3. Busse WW, Lemanske RF. Asthma. N Engl J Med. 2001;344:350–362
  4. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001;164:S1–S5
  5. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157–162
  6. Infuhr D, Crameri R, Lamers R, Achatz G. Molecular and cellular targets of anti-IgE antibodies. Allergy. 2005;60:977–985
  7. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004;113:297–302
  8. MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438–1445
  9. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112:1147–1154
  10. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol. 2009;123:107–113e3
  11. MacGlashan D. IgE and FcepsilonRI regulation. Clin Rev Allergy Immunol. 2005;29:49–60
  12. Malveaux FJ, Conroy MC, Adkinson NF, Lichtenstein LM. IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest. 1978;62:176–181
  13. Foster B, Metcalfe DD, Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcepsilonRI: correlation with serum IgE and allergic asthma. J Allergy Clin Immunol. 2003;112:1132–1138
  14. Global Initiative for Asthma (GINA) . Global strategy for asthma management and prevention. http:///www.ginasthma.comAvailable from:
  15. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma European network for understanding mechanisms of severe asthma. Eur Respir J. 2003;22:470–477
  16. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP, et al. Severe asthma in adults: what are the important questions?. J Allergy Clin Immunol. 2007;119:1337–1348
  17. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, lung, and blood Institute’s severe asthma Research Program. J Allergy Clin Immunol. 2007;119:405–413
  18. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–190
  19. Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966–1973
  20. Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261
  21. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316
  22. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101:1483–1492
  23. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002;2:151–161
  24. EMEA Xolair® SmPC Available from http://www.emea.europa.eu/humandocs/PDFs/EPAR/Xolair/H-606-PI-en.pdf
  25. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004;114:527–530
  26. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583–593
  27. van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, Mauad T, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009;64:72–80
  28. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459–465

PII: S0954-6111(10)00332-X

doi: 10.1016/j.rmed.2010.07.011

Respiratory Medicine
Volume 104, Issue 11 , Pages 1608-1617 , November 2010

Article Tools

* Image Usage & Resolution